SUMMARY
Coding variants in the microglial TREM2 ectodomain differentially (R47H> R62H) increase the risk of Alzheimer’s disease (AD). To define mechanisms responsible, we characterised neuropathology and transcriptomic responses in heterozygotes for these TREM2 variant alleles (TREM2var) and for common allele homozygotes (CV) in non-diseased and AD brain cortical tissue from 58 donors. Increased neurodegeneration in the TREM2var AD cortex was associated with genotype-dependent reductions in expression of Disease Associated Microglia (DAM) genes and increased expression of complement and Type I and II interferon pathways in microglia, phagocytosis and amyloid binding pathways and Disease Associated Astrocyte (DAA) genes in astrocytes, and growth factor, ubiquitination and apoptotic pathways in neurons. The microglial phenotypes and secondary differences in tissue β-amyloid deposition and in astrocyte and neuronal responses describe a variably partial loss of TREM2 function with variant alleles (R47H>R62H) relative to CV and suggest mechanisms that could account for differences in genetic risks conferred.
Competing Interest Statement
This study also was supported by an investigator initiated grant from Biogen IDEC to PMM and JSJ. PMM has received consultancy fees from Roche, Celgene, and Neurodiem. He has received honoraria or speakers' fees from Novartis and Biogen and has received research or educational funds from Biogen and Novartis.
Funding Statement
Infrastructure, including particularly the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility and the Imperial BRC Genomics Facility, was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). ST was supported by an "Early Postdoc Mobility" scholarship (P2GEP3_191446) from the Swiss National Science Foundation and a "Clinical Medicine Plus" scholarship from the Prof Dr Max Cloetta Foundation (Zurich, Switzerland). JH acknowledges support from the Dolby Foundation and the UK DRI. PMM acknowledges generous personal support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. This work was supported by a grant to PMM from the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. The study is an output from the UK Dementia Institute Multi-omics Atlas Project for Alzheimer's Disease (MAP-AD; map-ad.org).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of London Neurodegeneration [King's College London] gave ethical approval for this work Ethics committee of Newcastle Brain Tissue Resource gave ethical approval for this work Ethics committee of Queen's Square Brain Bank [UCL] gave ethical approval for this work Ethics committee of Manchester Brain Bank gave ethical approval for this work Ethics committee of Oxford Brain Bank gave ethical approval for this work Ethics committee of Parkinson's UK [Imperial College London] Brain Bank gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# joint senior authors
Data Availability
The full snRNAseq data will be made available for download from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) upon publication.
